The FDA may grant accelerated approval for cancer drugs that treat serious conditions and fill an unmet medical need, based on a surrogate endpoint. A surrogate endpoint is a marker, such as tumor shrinkage, that is reasonably likely to predict clinical benefit. Accelerated approval allows patients earlier access to promising new treatments, but requires further post-marketing studies to confirm the drug’s benefits.
